CoChat

Leucine Rich α-2 Glycoprotein: A Novel Neutrophil Granule Protein and Modulator of Myelopoiesis

Open access

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Leucine-rich α2 glycoprotein (LRG1), a serum protein produced by hepatocytes, has been implicated in angiogenesis and tumor promotion. Our laboratory previously reported the expression of LRG1 in murine myeloid cell lines undergoing neutrophilic granulocyte differentiation. However, the presence of LRG1 in primary human neutrophils and a role for LRG1 in regulation of hematopoiesis have not been previously described. Here we show that LRG1 is packaged into the granule compartment of human neutrophils and secreted upon neutrophil activation to modulate the microenvironment. Using immunofluorescence microscopy and direct biochemical measurements, we demonstrate that LRG1 is present in the peroxidase-negative granules of human neutrophils. Exocytosis assays indicate that LRG1 is differentially glycosylated in neutrophils, and co-released with the secondary granule protein lactoferrin. Like LRG1 purified from human serum, LRG1 secreted from activated neutrophils also binds cytochrome c. We also show that LRG1 antagonizes the inhibitory effects of TGFβ1 on colony growth of human CD34+ cells and myeloid progenitors. Collectively, these data invoke an additional role for neutrophils in innate immunity that has not previously been reported, and suggest a novel mechanism whereby neutrophils may modulate the microenvironment via extracellular release of LRG1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0170261

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 LRG1 is expressed during neutrophilic granulocyte differentiation and stored in lactoferrin (LF)-containing granules. (A) HL-60 cells were induced to differentiate with ATRA (1 uM) for 6 days, and soluble proteins extracted from cells harvested at days 0, 1, 3, and 6. Samples were subjected to immunoblot analysis to detect the presence of LRG1. Pure LRG1 in lane 1 is LRG1 purified from human serum included as a positive control. Proteins isolated from unstimulated human neutrophils (PMN lysate) are shown in the last lane. (B) Confocal immunofluorescence microscopy of purified human neutrophils incubated overnight with mouse anti-LRG1 (Abnova H00116844-M01, 1:100 dilution) and goat anti-LF (Santa Cruz sc-14431, 1:250 dilution), followed by donkey anti-mouse Alexafluor 488 (green, 1:500 dilution) and donkey anti-goat Alexafluor 594 (red, 1:2000 dilution) secondary antibodies. DAPI was used to stain nuclei (blue). LRG1 is visualized as green and LF as red. The yellow/orange color in the overlay panel is the result of green and red signals merging, indicating co-localization of LRG1 (green) with LF (red). Focal areas of non-merged green and red signals can also be seen, suggesting that LRG1 may also localize to non-LF-containing compartments. The data shown are representative of 3 independent experiments.
Fig 1 LRG1 is expressed during neutrophilic granulocyte differentiation and stored in lactoferrin (LF)-containing granules. (A) HL-60 cells were induced to differentiate with ATRA (1 uM) for 6 days, and soluble proteins extracted from cells harvested at days 0, 1, 3, and 6. Samples were subjected to immunoblot analysis to detect the presence of LRG1. Pure LRG1 in lane 1 is LRG1 purified from human serum included as a positive control. Proteins isolated from unstimulated human neutrophils (PMN lysate) are shown in the last lane. (B) Confocal immunofluorescence microscopy of purified human neutrophils incubated overnight with mouse anti-LRG1 (Abnova H00116844-M01, 1:100 dilution) and goat anti-LF (Santa Cruz sc-14431, 1:250 dilution), followed by donkey anti-mouse Alexafluor 488 (green, 1:500 dilution) and donkey anti-goat Alexafluor 594 (red, 1:2000 dilution) secondary antibodies. DAPI was used to stain nuclei (blue). LRG1 is visualized as green and LF as red. The yellow/orange color in the overlay panel is the result of green and red signals merging, indicating co-localization of LRG1 (green) with LF (red). Focal areas of non-merged green and red signals can also be seen, suggesting that LRG1 may also localize to non-LF-containing compartments. The data shown are representative of 3 independent experiments.CC BY · PubMed Central
Fig 2 LRG1 predominantly localizes to the secondary granule compartment of neutrophils. (A) Neutrophils were isolated from the peripheral blood of healthy donors as described, lysed by nitrogen cavitation, and the subcellular components separated by Percoll density centrifugation. The fractions are numbered 1 through 30, with fraction 1 corresponding to the most dense fraction and fraction 30 corresponding to the least dense fraction. Fractions were analyzed by ELISA for the presence of LRG1, MPO (primary granule marker), LF (secondary granule marker), and MMP9 (tertiary granule marker), and the results plotted as a function of dentisty. (B) Immunoblot analyses of fractions 1 through 21 from the same experiment presented in panel A, showing peak concentrations for MPO, LF, and MMP9 in fractions 2, 10, and 17, respectively, identical to the fractions containing the highest concentration of the indicated proteins as detected by ELISA shown in panel A. The peak concentration of LRG1 is detected in fraction 10, which corresponds to the peroxidase-negative LF-containing secondary granule compartment, consitant with the ELISA data presented in Panel A. The data shown are representative of 5 independent experiments.
Fig 2 LRG1 predominantly localizes to the secondary granule compartment of neutrophils. (A) Neutrophils were isolated from the peripheral blood of healthy donors as described, lysed by nitrogen cavitation, and the subcellular components separated by Percoll density centrifugation. The fractions are numbered 1 through 30, with fraction 1 corresponding to the most dense fraction and fraction 30 corresponding to the least dense fraction. Fractions were analyzed by ELISA for the presence of LRG1, MPO (primary granule marker), LF (secondary granule marker), and MMP9 (tertiary granule marker), and the results plotted as a function of dentisty. (B) Immunoblot analyses of fractions 1 through 21 from the same experiment presented in panel A, showing peak concentrations for MPO, LF, and MMP9 in fractions 2, 10, and 17, respectively, identical to the fractions containing the highest concentration of the indicated proteins as detected by ELISA shown in panel A. The peak concentration of LRG1 is detected in fraction 10, which corresponds to the peroxidase-negative LF-containing secondary granule compartment, consitant with the ELISA data presented in Panel A. The data shown are representative of 5 independent experiments.CC BY · PubMed Central
Fig 3 Activated neutrophils release LRG1. Human neutrophils isolated from healthy donors were pre-incubated in HBSS containing calcium and magnesium at 37°C for 5 minutes, then incubated for 20 minutes at 37°C with the indicated concentrations of calcium ionophore (CaI), PMA, fMLP, or no stimulant (0, negative control). The supernatants were collected, and immunoblot and ELISA analyses performed to detect and measure the amount of granule proteins released. (A) Immunoblot analysis of each condition from a representative experiment using antibodies for myeloperoxidase (MPO), lactoferrin (LF), and gelatinase (MMP9), as markers for primary, secondary, and tertiary granule release, respectively. The pattern of stimulation for release of LRG1 is most consistent with its release from LF-containing secondary granules. The data shown are representative of three independent experiments, each with a different normal donor. (B) ELISA analyses demonstrate release of LRG1 from neutrophils following stimulation with Cal or PMA but not with fMLP, a pattern consistent with the release of LF from secondary granules. The mean of three independent experiments is shown and error bars represent standard error (n = 3).
Fig 3 Activated neutrophils release LRG1. Human neutrophils isolated from healthy donors were pre-incubated in HBSS containing calcium and magnesium at 37°C for 5 minutes, then incubated for 20 minutes at 37°C with the indicated concentrations of calcium ionophore (CaI), PMA, fMLP, or no stimulant (0, negative control). The supernatants were collected, and immunoblot and ELISA analyses performed to detect and measure the amount of granule proteins released. (A) Immunoblot analysis of each condition from a representative experiment using antibodies for myeloperoxidase (MPO), lactoferrin (LF), and gelatinase (MMP9), as markers for primary, secondary, and tertiary granule release, respectively. The pattern of stimulation for release of LRG1 is most consistent with its release from LF-containing secondary granules. The data shown are representative of three independent experiments, each with a different normal donor. (B) ELISA analyses demonstrate release of LRG1 from neutrophils following stimulation with Cal or PMA but not with fMLP, a pattern consistent with the release of LF from secondary granules. The mean of three independent experiments is shown and error bars represent standard error (n = 3).CC BY · PubMed Central
Fig 4 Neutrophil-derived LRG1 is differentially glycosylated but retains affinity for cytochrome c. Neutrophil (PMN) lysates from healthy volunteers were prepared as described. PMN releasates were prepared by exposing isolated neutrophils to calcium ionophore and the resultant supernatants concentrated by ultrafiltration. (A) LRG1 purified from human serum, PMN lysate, and PMN granule releasate were left untreated (- lanes) or subjected to deglycosylation (+ lanes) using a commercially available protein deglycosylation kit, and immunoblot analysis performed using an antibody to human LRG1. Molecular weight markers (MM) are shown on the left. Neutrophil-derived LRG1 migrates with a higher molecular weight than serum-derived LRG1 (- lanes) but with the same molecular weight following deglycosylation (+ lanes), indicating different patterns of glycosylation of the native protein forms in PMNs compared to serum. The data shown are representative of three independent experiments, each with a different normal donor. (B) Purified cytochrome c was bound to a NHS-activated sepharose column. Releasate from PMNs stimulated with calcium ionophore (2 uM) was loaded onto the cytochrome c column. Bound proteins were eluted with an acetate buffer (pH 4) in 1 mL fractions, and subjected to immunoblot analysis with antibody to LRG1. Lane 1 is crude PMN releasate. The column flow through and wash is shown in lane 2. Eluate fractions are shown in lanes 3–8, with LRG1 detectable in fractions 3 and 4. Lane 9 is purified LRG1. The data shown are representative of three independent experiments.
Fig 4 Neutrophil-derived LRG1 is differentially glycosylated but retains affinity for cytochrome c. Neutrophil (PMN) lysates from healthy volunteers were prepared as described. PMN releasates were prepared by exposing isolated neutrophils to calcium ionophore and the resultant supernatants concentrated by ultrafiltration. (A) LRG1 purified from human serum, PMN lysate, and PMN granule releasate were left untreated (- lanes) or subjected to deglycosylation (+ lanes) using a commercially available protein deglycosylation kit, and immunoblot analysis performed using an antibody to human LRG1. Molecular weight markers (MM) are shown on the left. Neutrophil-derived LRG1 migrates with a higher molecular weight than serum-derived LRG1 (- lanes) but with the same molecular weight following deglycosylation (+ lanes), indicating different patterns of glycosylation of the native protein forms in PMNs compared to serum. The data shown are representative of three independent experiments, each with a different normal donor. (B) Purified cytochrome c was bound to a NHS-activated sepharose column. Releasate from PMNs stimulated with calcium ionophore (2 uM) was loaded onto the cytochrome c column. Bound proteins were eluted with an acetate buffer (pH 4) in 1 mL fractions, and subjected to immunoblot analysis with antibody to LRG1. Lane 1 is crude PMN releasate. The column flow through and wash is shown in lane 2. Eluate fractions are shown in lanes 3–8, with LRG1 detectable in fractions 3 and 4. Lane 9 is purified LRG1. The data shown are representative of three independent experiments.CC BY · PubMed Central
Fig 5 LRG1 modifies the effects of TGFβ on myeloid and hematopoietic progenitor cell growth. (A) HL-60 cell proliferation in the presence of increasing concentrations of TGFβ alone (blue diamonds) or TGFβ plus LRG1 (800 ng/mL, red squares) was assessed using the XTT assay. A dose-response reduction in cell proliferation as measured by the decreasing A490-A650 is observed with increasing concentrations of TGFβ that is mitigated by the addition of LRG1. The Student's t-test was used to determine the significance of the differences between control and LRG1 treated samples († p < 0.05) (n = 5). (B) Purified bone marrow-derived CD34+ cells were cultured in serum-free semi-solid media in the presence of TGFβ (10 ng/mL) with or without LRG1 at the indicated concentrations, and colony numbers scored. An increase in colony numbers relative to TGFβ1 treatment alone (0) is seen with increasing concentrations of LRG1. The Student's t-test was used to determine the significance of the differences between control and LRG1 treated samples († p < 0.05) (n = 3). (C) The effects of TGFβ alone (left panel) and TGFβ plus LRG1 (right panel) on colony formation and colony composition were analyzed. Upper two images in each panel. Representative light microscopy images of methocult plates on which bone marrow-derived CD34+ cells were cultured in the presence of TGFβ alone (left) or TGFβ with LRG1 (right). Lower two images in each panel. Wright-Giemsa staining of cells plucked from individual colonies from the methocult plates in the upper images is shown. Cells were grown as described in (B) in the presence of TGFβ (10 ng/mL) with or without LRG1 (0.625 ug/mL). LRG1 mitigates the inhibitory effect of TGFβ on the growth and size of colony-forming units-granulocyte monocyte (CFU-GM). The data shown are representative of five independent experiments, each with a different normal donor.
Fig 5 LRG1 modifies the effects of TGFβ on myeloid and hematopoietic progenitor cell growth. (A) HL-60 cell proliferation in the presence of increasing concentrations of TGFβ alone (blue diamonds) or TGFβ plus LRG1 (800 ng/mL, red squares) was assessed using the XTT assay. A dose-response reduction in cell proliferation as measured by the decreasing A490-A650 is observed with increasing concentrations of TGFβ that is mitigated by the addition of LRG1. The Student's t-test was used to determine the significance of the differences between control and LRG1 treated samples († p < 0.05) (n = 5). (B) Purified bone marrow-derived CD34+ cells were cultured in serum-free semi-solid media in the presence of TGFβ (10 ng/mL) with or without LRG1 at the indicated concentrations, and colony numbers scored. An increase in colony numbers relative to TGFβ1 treatment alone (0) is seen with increasing concentrations of LRG1. The Student's t-test was used to determine the significance of the differences between control and LRG1 treated samples († p < 0.05) (n = 3). (C) The effects of TGFβ alone (left panel) and TGFβ plus LRG1 (right panel) on colony formation and colony composition were analyzed. Upper two images in each panel. Representative light microscopy images of methocult plates on which bone marrow-derived CD34+ cells were cultured in the presence of TGFβ alone (left) or TGFβ with LRG1 (right). Lower two images in each panel. Wright-Giemsa staining of cells plucked from individual colonies from the methocult plates in the upper images is shown. Cells were grown as described in (B) in the presence of TGFβ (10 ng/mL) with or without LRG1 (0.625 ug/mL). LRG1 mitigates the inhibitory effect of TGFβ on the growth and size of colony-forming units-granulocyte monocyte (CFU-GM). The data shown are representative of five independent experiments, each with a different normal donor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 77

Metadata

Authors
Druhan, L. J., Lance, A., Li, S., Price, A. E., Emerson, J. T., Baxter, S. A., Gerber, J. M., & Avalos, B. R.
Affiliations
  • Carolinas Healthcare System (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Avalos, Belinda R.
Venue
PLOS ONE
Published
2017-01-12
Volume
12
Issue
1
Pages
e0170261
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2572211926
Cited by
77
References
36
Citations by year
2026: 7 · 2025: 12 · 2024: 7 · 2023: 4 · 2022: 15 · 2021: 12 · 2020: 12 · 2019: 6 · 2018: 2
FWCI
2.48
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • UNC Libraries
Funders
American Society of Hematology (MMSAP)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Health Sciences › Medicine › Hematology › Blood disorders and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
Keywords
LRG1, neutrophils, neutrophil granules, myelopoiesis, lactoferrin, cytochrome c binding, TGF-β1, CD34+ cells, myeloid progenitor cells, glycosylation, neutrophil activation, extracellular secretion, innate immunity, hematopoietic regulation
MeSH terms
Cell Differentiation, Cells, Cultured, Chromatography, High Pressure Liquid, Exocytosis, Glycoproteins, Glycosylation, Humans, Lactoferrin, Neutrophils, Protein Binding, Tretinoin, Signal Transduction, Neutrophil Activation, HL-60 Cells, Antigens, CD34, Matrix Metalloproteinase 9, Myelopoiesis, Cytochromes c, Transforming Growth Factor beta1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Leucine Rich α-2 Glycoprotein: A Novel Neutrophil Granule Protein and Modulator of Myelopoiesis. https://app.cochat.ai/papers/10.1371/journal.pone.0170261
The paper
Druhan, L. J., Lance, A., Li, S., Price, A. E., Emerson, J. T., Baxter, S. A., Gerber, J. M., & Avalos, B. R. (2017). Leucine Rich α-2 Glycoprotein: A Novel Neutrophil Granule Protein and Modulator of Myelopoiesis. PLOS ONE. https://doi.org/10.1371/journal.pone.0170261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.